PerkinElmer releases new KRAS investigation kits

By Kate Madden Yee, The Science Advisory Board contributing writer

August 16, 2021 -- PerkinElmer has released four new test kits designed to help researchers better understand KRAS protein structures and mutations. The kits will enable cancer researchers to accelerate the identification and optimization of therapeutic leads, the company said.

The new kits expand PerkinElmer's existing portfolio of homogeneous time resolved fluorescence (HTRF) and AlphaLISA offerings, both of which are ready-to-use assays for KRAS/SOS1 inhibition analysis in a no-wash format. Each kit comes with recombinant proteins, detection reagents, and assay buffers, PerkinElmer said.

"KRAS mutations are present in approximately 25% of tumors, making them one of the most common gene mutations linked to cancer," said Alan Fletcher, PhD, senior vice president of life sciences and technology, in a company statement. "Because KRAS mutations are found in numerous types of cancer, from lung to colorectal to pancreatic cancers, it's a prime drug target."

The company also offers early-stage drug discovery services, with assays, cell lines, microplates, and plate readers, as well as later-stage research, with high-content screening, image analysis and management, and automated liquid handling.

PerkinElmer posts growth in Q2
PerkinElmer posted revenue and operating income increases in its second quarter 2021.
PerkinElmer agrees to acquire Sirion Biotech
PerkinElmer has entered into an agreement to acquire Sirion Biotech, a provider of viral vector-based technology for cell and gene therapies. The acquisition...
PerkinElmer contributes resources to public cell painting dataset
PerkinElmer is providing its PhenoVue cell painting kits to the Joint Undertaking in Morphological Profiling-Cell Painting consortium to help speed drug...
PerkinElmer to acquire Nexcelom for $260M
PerkinElmer has entered into an agreement to acquire life sciences instrumentation firm Nexcelom Bioscience for $260 million, a deal that is expected...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter